Dr. Yong-an Ye’s Team: Predicting Virological Recurrence in Chronic Hepatitis B with Machine Learning After Entecavir Discontinuation

Dr. Yong-an Ye’s Team: Predicting Virological Recurrence in Chronic Hepatitis B with Machine Learning After Entecavir Discontinuation

Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common. Early virological recurrence typically predicts disease flare-up; however, there are limited biomarkers for assessing the risk of virological recurrence after treatment cessation. Dr. Yong-an Ye 's team at the Dongzhimen Hospital of Beijing University of Chinese Medicine (Chinese Institute of Traditional Chinese Medicine for Liver Diseases) conducted a prospective randomized controlled trial (RCT) and constructed a new predictive model based on serological markers to identify the risk of early virological recurrence in Chinese CHB patients after discontinuing entecavir (ETV). The findings were presented in poster format during the 58th European Association for the Study of the Liver (EASL) International Liver Congress 2023
Dr. Minghua Zheng’s Team: AI-Based Digital Pathology Provides New Insights into NASH Fibrosis Reversal Induced by Lifestyle Intervention

Dr. Minghua Zheng’s Team: AI-Based Digital Pathology Provides New Insights into NASH Fibrosis Reversal Induced by Lifestyle Intervention

Non-Alcoholic Steatohepatitis (NASH) is a common cause of chronic liver disease, and the degree of liver fibrosis is an important factor determining its clinical prognosis. Lifestyle intervention is the cornerstone of NASH treatment and can improve liver fibrosis. However, the specific effects of lifestyle intervention on micro-level liver fibrosis reversal are not clear. Dr. Minghua Zheng's team at the First Affiliated Hospital of Wenzhou Medical University used quantitative digital pathology technology qFibrosis to assess liver fibrosis characteristics in depth and explore the impact of the intensity of lifestyle intervention on NASH fibrosis. The relevant results were selected for poster presentation at the 58th Annual Meeting of the European Association for the Study of the Liver (EASL2023) and the 2023 EASL Congress.
ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future

ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain from October 20 to 24. The Oncology Frontier Reporting Team delved into the frontiers of international advancements, witnessing the progress of China's anti-cancer efforts on the global stage. Professor Feng Wang from Sun Yat-sen University Cancer Center presented an important oral report at this conference. In an interview with "Oncology Frontier," Professor Feng Wang shared insights into two studies and highlights in the field of gastric cancer at the ESMO conference. This issue compiles relevant content for readers.
WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.